Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling

Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL- Tumors

(2014) N. Larmonier et al.   JOURNAL OF IMMUNOLOGY

Human Memory B Lymphocyte Subsets Fulfill Distinct Roles in the Anti-Polysaccharide and Anti-Protein Immune Response

(2014) L. Moens et al.   JOURNAL OF IMMUNOLOGY

Imatinib mesylate directly impairs class switch recombination through down-regulation of AID: its potential efficacy as an AID suppressor

(2012) T. Kawamata et al.   BLOOD

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy

(2012) S Mustjoki et al.   LEUKEMIA

A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies

(2011) G. L. Chen et al.   BLOOD

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

(2011) Paola Di Gion et al.   CLINICAL PHARMACOKINETICS

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation

(2011) A Kreutzman et al.   LEUKEMIA

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

(2011) Vinod P Balachandran et al.   NATURE MEDICINE

Humoral and Cellular Immunity to Primary H1N1 Infection in Patients with Hematologic Malignancies following Stem Cell Transplantation

(2010) Paula Garland et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host

(2010) H. de Lavallade et al.   HAEMATOLOGICA

Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling

(2010) J. Chen et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

(2010) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Proteomics Analysis of Cellular Imatinib Targets and their Candidate Downstream Effectors

(2010) Susanne B. Breitkopf et al.   JOURNAL OF PROTEOME RESEARCH

Lck is a key target of imatinib and dasatinib in T-cell activation

(2010) K C Lee et al.   LEUKEMIA

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults

(2010) Neil French et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily

(2009) C. Sillaber et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Tyrosine kinases and their substrates in B lymphocytes

(2009) Tomohiro Kurosaki et al.   IMMUNOLOGICAL REVIEWS

Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro

(2009) Stephen J. Blake et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

PLC-γ2 is essential for formation and maintenance of memory B cells

(2009) Masaki Hikida et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

(2009) S Mustjoki et al.   LEUKEMIA

Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib

(2008) R. Weichsel et al.   CLINICAL CANCER RESEARCH

The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro

(2008) Stephen Blake et al.   CLINICAL IMMUNOLOGY

Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens

(2008) Fei Fei et al.   EXPERIMENTAL HEMATOLOGY

Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo

(2008) Cara K. Fraser et al.   EXPERIMENTAL HEMATOLOGY

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

(2008) Hugues de Lavallade et al.   JOURNAL OF CLINICAL ONCOLOGY

Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells

(2008) Kristina E. Halcomb et al.   MOLECULAR IMMUNOLOGY